- Research article
- Open Access
Protective effect of anti-SUAM antibodies on Streptococcus uberis mastitis
© Almeida et al. 2015
Received: 14 July 2015
Accepted: 15 October 2015
Published: 19 November 2015
In the present study, the effect of anti-recombinant Streptococcus uberis adhesion molecule (SUAM) antibodies against S. uberis intramammary infections (IMI) was evaluated using a passive protection model. Mammary quarters of healthy cows were infused with S. uberis UT888 opsonized with affinity purified anti-rSUAM antibodies or hyperimmune sera. Non-opsonized S. uberis UT888 were used as a control. Mammary quarters infused with opsonized S. uberis showed mild-to undetectable clinical symptoms of mastitis, lower milk bacterial counts, and less infected mammary quarters as compared to mammary quarters infused with non-opsonized S. uberis. These findings suggest that anti-rSUAM antibodies interfered with infection of mammary gland by S. uberis which might be through preventing adherence to and internalization into mammary gland cells, thus facilitating clearance of S. uberis, reducing colonization, and causing less IMI.
Environmental streptococci, particularly Streptococcus uberis, account for a significant proportion of mastitis in lactating and nonlactating cows [1–3], and heifers . Current prevention and control programs originally designed for the control of contagious mastitis pathogens such as Streptococcus agalactiae are only marginally effective against S. uberis. Susceptibility to S. uberis mastitis varies during the different stages of the lactation cycle, showing the highest prevalence during the early nonlactating and periparturient periods [5, 6].
Research conducted in our lab lead to the discovery of a novel S. uberis virulence factor identified as S. uberis adhesion molecule (SUAM) . SUAM is a fibrillar surface protein associated with the S. uberis cell wall by a hydrophobic region, and has affinity for lactoferrin (LF). Further in vitro studies showed that SUAM plays a central role during the early events of S. uberis IMI via adherence to and internalization into bovine mammary epithelial cells (BMEC). Mechanisms underlying the pathogenic involvement of SUAM rely partially on its affinity for LF, which together with a putative receptor on the surface of BMEC creates a molecular bridge which facilitates adherence to and internalization of S. uberis into BMEC [7–9]. We also discovered that SUAM has a LF-independent domain that also mediates adherence and internalization, and that anti-SUAM antibodies blocked both pathogenic mechanisms . Further studies using a SUAM deletion mutant showed that adherence and internalization of the SUAM mutant strain into BMEC was markedly reduced as compared with the parent S. uberis strain .
In an attempt to enhance mammary immunity during the late nonlactating and periparturient periods, we conducted a vaccination study using recombinant SUAM (rSUAM) as antigen. Results showed that significant increases in anti-rSUAM antibodies in serum and mammary secretions can be achieved during these high mastitis prevalence periods . Furthermore, vaccination-induced anti-rSUAM antibodies inhibited in vitro adherence to and internalization of S. uberis into BMEC . The purpose of the present study was to extend our observations by using an in vivo approach to evaluate the effect of anti-rSUAM antibodies on the pathogenesis of S. uberis IMI.
Materials and methods
Recombinant SUAM was purified as described . Concentrated rSUAM was sent to Quality Bioresources, Inc. (Seguin, TX, USA) for production of antibodies. Anti-rSUAM antibodies were affinity purified from sera of rSUAM-immunized steers using rSUAM conjugated to Ultra Link Biosupport (Thermo Scientific, Rockford, IL, USA) and eluted with 0.1 M citrate buffer. Final antibody concentration as determined by ELISA was 21.0 mg/mL.
Bacterial strain, culture conditions and preparation of challenge suspension
Streptococcus uberis UT888, a strain originally isolated from a cow with chronic mastitis, was used in this study . Frozen stocks of S. uberis UT888 were thawed in a 37 °C water bath, streaked onto blood agar plates (BAP), and incubated for 16 h at 37 °C in a CO2: air balanced incubator. A single colony from the BAP culture was used to inoculate 50 mL of Todd Hewitt broth (THB, Becton–Dickinson, Franklin Lakes, NJ, USA) and incubated for 16 h at 37 °C in an orbital rocking incubator at 150 rpm. The resulting suspension was then diluted in PBS (pH 7.4) to a concentration of 4.0 log10 colony forming units/mL (CFU/mL), mixed with anti-rSUAM antibodies at a final concentration of 15.0 mg/mL and further incubated for 1 h at 37 °C. The challenge suspension used for positive control mammary quarters was prepared in parallel but omitting the addition of anti-rSUAM antibodies.
Twenty mastitis-free (negative bacteriological culture and milk SCC <250 000 cells/mL at quarter level) Holstein cows in their 2nd and 3rd lactations and in their first 60 days of the lactation were used. Cows were allocated randomly to the experimental (n = 10) or positive control (n = 10) groups. One mammary quarter of each cow in the experimental group was infused with S. uberis UT888 opsonized with affinity-purified anti-rSUAM antibodies (opsonized S. uberis). One uninfected mammary quarter of cows in the control group was infused with non-opsonized S. uberis UT888. Non-infused quarters were used as negative controls. The experimental IMI protocol was approved by The University of Tennessee Institutional Animal Care and Use Committee.
Clinical assessment of animals following challenge
Mammary gland and milk evaluation and scoring.
Slight, firmness, swelling
Firm, moderate swelling
Stringy, watery, bloody
Hard, severe swelling
Uncomfortable, irritable, kicks
Mammary quarters were considered infected and classified as IMI as described . Subclinical mastitis was defined as quarters without clinical signs having positive isolation of S. uberis (≥500 colony forming units per mL (CFU/mL)) and/or corresponding increase of SCC (>2.5 × 105). Clinical mastitis was defined as quarters having scores of >2 for milk and mammary appearance.
Milk sample evaluation
Samples of foremilk were collected aseptically from each mammary quarter 7 days before challenge (CH − 7), immediately before challenge, twice daily at milking from CH0 through CH + 7 and once daily at CH + 10 and CH + 14. Microbiological evaluation of milk samples was done following procedures recommended by NMC. Identification of S. uberis strains used was as described [4, 13]. Milk somatic cell counts (SCC) were analyzed at the Dairy Herd Improvement Association Laboratory, Knoxville, TN, USA.
Data on mammary scores, SCC and bacterial counts were analyzed using SAS software (Cary, NC, USA). A mixed model repeated measures (autoregressive variance structure) with cow as the subject was used to compare strains, time, and their interaction.
Least squares means were separated using Fisher’s protected LSD at the 5% significance level. Variables were examined for normality (Shapiro–Wilk >0.90) and equal variance, which showed bacterial counts needed log transformation.
Somatic cell counts
In a previous communication, we reported a novel virulence factor from S. uberis identified as S. uberis adhesion molecule (SUAM) . Further research showed that this molecule had a central role on adherence and internalization of S. uberis into BMEC and that anti SUAM antibodies from immunized cows were able to reduce adherence to and internalization of S. uberis into BMEC . Even though these results were very promising, the lack of data generated from in vivo approaches was the piece missing in our research. To solve this void, we conducted an in vivo passive protection assay to specifically answer the question about the protective effect of anti-SUAM antibodies.
Passive immunity is the transfer of antibodies from one individual to another and occurs naturally when maternal antibodies are transferred to the fetus through the placenta, or when antibodies specific for a pathogen or toxin are passively transferred to achieve immediate protection against a specific pathogen . Passive protection is the status obtained by passive immunity and assays directed to test the efficacy of specific antibodies to neutralize pathogens or toxins are known as in vivo passive protection assay. Typically, in vivo passive protection assay consists of treatment of susceptible individuals with specific antibodies before experimental exposure to the target pathogen. Protective effect of the test antibodies is determined by measuring the reduction of symptoms or progression of the disease as compared to non-treated controls [15–17]. In this study, we used a variation of such a method. In our approach, S. uberis was opsonized with anti-rSUAM antibodies prior to infusion into healthy mammary glands of dairy cows and similarly as a control the same non-treated strain infused into healthy mammary glands. Results showed that mammary quarters infused with S. uberis opsonized with anti-rSUAM antibodies had less clinical mastitis, with mild symptoms, and lower bacterial counts in milk as compared to control quarters. Somatic cells counts and bacterial counts in CFU/mL were lower in mammary glands infused with S. uberis opsonized with anti-rSUAM antibodies from CH + 2 to CH + 5. In spite of these differences, by CH + 10 CFU/mL were higher in milk of quarters infused with opsonized S. uberis that in the control group. Such differences could be due to the fact that in absence of active production of anti-SUAM antibodies, a fraction of S. uberis not affected by the blocking effect of these antibodies or innate defenses of the mammary gland follow the pathogenic pathways of S. uberis IMI, resulting in augmented CFU/mL in the milk of these cows. It is important to note that the concentration of anti-rSUAM antibodies used (15.0 mg/mL) was about 5 times more concentrated than normal IgG values (~3 mg/mL) during the peripartum period in dairy cows, as reported . This suggests that optimization of local antibody responses through strategic vaccination schedules and routes of administration need to be achieved in order to confer effective protection during the peripartum period.
Findings reported in this communication indicate that anti-rSUAM antibodies have a protective effect against S. uberis IMI, possibly either by blocking adherence and internalization of S. uberis into host cells , and/or likely by mediating the S. uberis phagocytosis by neutrophils and macrophages in the mammary glands. These findings confirm our previous in vitro observations about the protective role of anti-rSUAM antibodies  and establish the value of our in vitro experimental model based on cocultures of BMEC with S. uberis as an initial step in identification of S. uberis virulence factors.
In conclusion, results from this investigation demonstrated that anti-rSUAM antibodies partially protected mammary glands from S. uberis infection following experimental challenge most likely by preventing adhesion and invasion of bacteria into host cells and/or through opsono-phagocytic removal of bacteria by phagocytic cells.
The authors declare that they have no competing interests.
RAA, OKD, and SPO participated in design of the study, carried out the experiments and statistical analysis, and contributed to drafting of the manuscript. MEP was responsible for elaboration of rSUAM, and SIH conducted the microbiology analysis. MJL, LJS, GMP, OKD as well as RAA and SIH participated in conduction of animal experiments of this study. All authors read and approved the final manuscript.
This project was supported by the Agriculture and Food Research Initiative Competitive Grant no. 2011-67015-30168 from the USDA National Institute of Food and Agriculture, and the AgResearch Innovation Grant Program from The University of Tennessee Institute of Agriculture.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Oliver SP (1988) Frequency of isolation of environmental mastitis-causing pathogens and incidence of new intramammary infection during the nonlactating period. Am J Vet Res 49:1789–1793PubMedGoogle Scholar
- Hogan JS, Smith KL, Hoblet KH, Schoenberger PS, Todhunter DA, Hueston WD, Pritchard DE, Bowman GL, Heider LE, Brockett BL (1989) Field survey of clinical mastitis in low somatic cell count herds. J Dairy Sci 72:1547–1556View ArticlePubMedGoogle Scholar
- Leigh JA (1999) Streptococcus uberis: a permanent barrier to the control of bovine mastitis? Vet J 157:225–238View ArticlePubMedGoogle Scholar
- Oliver SP, Gillespie BE, Jayarao BM (1998) Detection of new and persistent Streptococcus uberis and Streptococcus dysgalactiae intramammary infections by polymerase chain reaction-based DNA fingerprinting. FEMS Microbiol Lett 160:69–73View ArticlePubMedGoogle Scholar
- Oliver SP, Sordillo LM (1989) Approaches to the manipulation of mammary involution. J Dairy Sci 72:1647–1664View ArticlePubMedGoogle Scholar
- McDougall S, Arthur DG, Bryan MA, Vermunt JJ, Weir AM (2007) Clinical and bacteriological response to treatment of clinical mastitis with one of three intramammary antibiotics. N Z Vet J 55:161–170View ArticlePubMedGoogle Scholar
- Almeida RA, Luther DA, Park HM, Oliver SP (2006) Identification, isolation, and partial characterization of a novel Streptococcus uberis adhesion molecule (SUAM). Vet Microbiol 115:183–191View ArticlePubMedGoogle Scholar
- Rejman JJ, Turner JD, Oliver SP (1994) Characterization of lactoferrin binding to the MAC-T bovine mammary epithelial cell line using a biotin-avidon technique. Int J Biochem 26:201–206View ArticlePubMedGoogle Scholar
- Patel D, Almeida RA, Dunlap JR, Oliver SP (2009) Bovine lactoferrin serves as a molecular bridge for internalization of Streptococcus uberis into bovine mammary epithelial cells. Vet Microbiol 137:297–301View ArticlePubMedGoogle Scholar
- Chen X, Kerro-Dego O, Almeida RA, Fuller TE, Luther DA, Oliver SP (2011) Deletion of sua gene reduces the ability of Streptococcus uberis to adhere to and internalize into bovine mammary epithelial cells. Vet Microbiol 147:426–434View ArticlePubMedGoogle Scholar
- Prado ME, Almeida RA, Ozen C, Luther DA, Lewis MJ, Headrick SJ, Oliver SP (2011) Vaccination of dairy cows with recombinant Streptococcus uberis adhesion molecule induces antibodies that reduce adherence to and internalization of S. uberis into bovine mammary epithelial cells. Vet Immunol Immunopathol 141:201–208View ArticlePubMedGoogle Scholar
- Zadoks RN, Gillespie BM, Barkema HW, Sampion OC, Oliver SP, Schukken YH (2003) Clinical, epidemiological and molecular characteristics of Streptococcus uberis infections in dairy herds. Epidemiol Infect 130:335–349PubMed CentralView ArticlePubMedGoogle Scholar
- Jayarao BM, Gillespie BE, Lewis MJ, Dowlen HH, Oliver SP (1999) Epidemiology of Streptococcus uberis intramammary infections in a dairy herd. Zentralbl Veterinarmed B 46:433–442PubMedGoogle Scholar
- Ghaffar A, Haqqi T (2009) Immunization. In: Microbiology and Immunology On-Line Textbook: USC School of Medicine. http://www.microbiologybook.org/ghaffar/immunization-ver2.htm. Accessed 10 July 2015
- Foo DGW, Alonso S, Chow VTK, Poh CL (2007) Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9:1299–1309View ArticlePubMedGoogle Scholar
- Hewetson JF, Little SF, Ivins BE, Johnson WM, Pittman PR, Brown JE, Norris SL, Nielsen CJ (2008) An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. Vaccine 26:4262–4266View ArticlePubMedGoogle Scholar
- Ye J, Shao H, Hickman D, Angel M, Xu K, Cai Y, Song H, Fouchier RAM, Qin A, Perez DR (2010) Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice. Clin Vaccine Immunol 17:1363–1370PubMed CentralView ArticlePubMedGoogle Scholar
- Guidry J, Butler JE, Pearson PE, Weinland BT (1980) IgA, igG1, IgG2, IgM, and BSA in serum and mammary secretion throughout lactation. Vet Immunol Immunopathol 1:329–341View ArticlePubMedGoogle Scholar